The development of bispecific antibodies targeting both PD-L1 and HHLA2 signaling has the potential to stimulate the immunogenic pathway and enhance responses to ICIs, making it a promising approach in cancer immunotherapy (Wang et al. 2019). The gene discussed is HHLA2; the disease is cancer.